Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01075217 · ClinicalTrials.gov registry record · Phase 4
Isovue in Peripheral Digital Subtraction Angiography (DSA)
A Phase 4 study of Peripheral Arterial Occlusive Disease, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 174
- Enrollment target
- 1
- Study location
NCT01075217: Completed Phase 4 study of Peripheral Arterial Occlusive Disease, sponsored by Bracco Diagnostics.
NCT01075217 is a Phase 4 study of Peripheral Arterial Occlusive Disease that has completed, run by Bracco Diagnostics. The registered enrollment target is 174 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01075217, a Phase 4 study of Peripheral Arterial Occlusive Disease, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 174 participants
- Enrollment target
- 1
- Study location
Study Summary
No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
Primary Outcome
The 10-centimeter Pain VAS was completed by the Group 1 patients to assess his/her pain level (not scoring heat separately from pain) in the lower extremity of interest. The scale was 0 to 10 cm, with the left end (0 cm)of the scale indicating no pain and the right end (10 cm) of the scale indicating the worst pain. The 10-centimeter Pain VAS (excluding Heat assessment, which was separately assessed) was completed by the Group 2 patients to assess his/her pain level in the lower extremity of in
Conditions Studied
Interventions
- DRUG iopamidol
- DRUG iodixanol
Study Locations (1)
New Jersey
- Bracco Diagnostics - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT01075217 record still lists
NCT01075217 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Peripheral Arterial Occlusive Disease appearing as the primary indexed condition, and to 2 interventions - of which iopamidol is the first listed.
NCT01075217 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT01075217 about?
NCT01075217 is a clinical study titled "Isovue in Peripheral Digital Subtraction Angiography (DSA)". No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
What is the current status of trial NCT01075217?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 174 participants. The study started on 2010-04. Estimated completion is 2011-12.
What conditions does trial NCT01075217 study?
This clinical trial studies the following conditions: Peripheral Arterial Occlusive Disease.
What interventions are being tested in trial NCT01075217?
The interventions under investigation include: iopamidol (DRUG), iodixanol (DRUG).
Who is sponsoring clinical trial NCT01075217?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01075217 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Occlusive Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01075217's enrollment target sits among peer trials
174 480th of 2000 higher than 1,521 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia